Slide 1: Q2:23 Results Conference Call
Exhibit 99.2 Q2:23 Results Conference Call August 1, 2023 H E L P I N G H U M A N S H E A L
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth
Slide 3: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Additional forward-looking statements may be identified by words such as believe, expect, may, plan, potential, will, preliminary, and similar expressions, and are based on management's current beliefs and expectations. Forward-looking statements are subject to ris
Slide 4: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer
Slide 5: Q2:23 Highlights
Q2:23 Highlights Highest quarterly net sales in nearly Net Sales Gross Margin 4 years Improving financial profile, $81.3MM 83.3% particularly with improving gross margins Net Sales Adjusted EBITDA Strategic realignment and suspension Year/Year Growth of knee osteoarthritis program $14.1MM +21.5% 17%
Slide 6: Progress With Strategic Priorities
Progress With Strategic Priorities Build leadership position in Develop opportunities in Demonstrate corporate Wound & Surgical adjacent markets discipline around expenses • Solid growth in all sites-of-service• Strategic realignment • Accelerating sustainable sharpens our focus profitability and ca
Slide 7: Doug Rice, Chief Financial Officer
Doug Rice Chief Financial Officer
Slide 8: Q2:23 Net Sales
Q2:23 Net Sales Site-of-Service Product Mix & Year/Year Growth $81.3 Other $66.9 $10.9MM +38% Private Hospital Office $46.6MM $23.8MM +17% +25% Q2:22 Q2:23 8 $ millions
Slide 9: Q2:23 Gross Profit & Gross Margins
Q2:23 Gross Profit & Gross Margins Year/year margin $67.7 expansion driven by yield improvement $60.0 $59.3 $55.5 $55.1 and favorable product mix with increased $49.0 sales in higher margin care settings 83.3% 83.1% 82.7% 82.3% 82.0% Remain focused on 80.7% driving gross margin percentage back into
Slide 10: Q2:23 Operating Expenses
Q2:23 Operating Expenses Q2:22 $55.8 $51.9 Q2:23 Expense discipline more than offset higher commissions to drive strong improvement in Adjusted $8.5 $5.5 EBITDA % of net sales 83% 64% 8% 11% R&D SG&A $14.1 Restructuring charge associated with strategic $1.2 realignment more than offset meaningful re
Slide 11: Q2:23 Results by Business Segment
Q2:23 Results by Business Segment ($ millions) Q2:22 Q2:23 Net Sales $66.1 $80.5 • Q2:23 Wound & Surgical Segment (10.8) (12.7) Cost of Sales Wound & Contribution of $27.6 million or 34.3% of Selling, General and Administrative Expense (38.7) (38.5) Wound & Surgical net sales compared to $14.2 Surgi
Slide 12: Liquidity Highlights
Liquidity Highlights $68.7MM $7.8MM Cash & Equivalents Operating Cash Flow Cash & Debt Q2:23 at June 30, 2023 Cash Flows $48.8MM $7.5MM Long-Term Debt Free Cash Flow 12
Slide 13: Joe Capper, Chief Executive Officer
Joe Capper Chief Executive Officer
Slide 14: Q2 Summary
Q2: 23 Summary Q2:23 & 1H:23 Net Sales Growth of Nearly 22% Year-Over-Year Q2:23 Gross Margin of 83.3% Q2:23 Adjusted EBITDA of $14.1 Million (17.4% of Net Sales) Strong Performance Increased Our Cash Balance by $7.5 Million from Q1:23 to Q2:23 During 1H:23 Continued Roll Out of New Products in the
Slide 15: 2023 Outlook
* 2023 Outlook 2023 Continues to Shape Up to be a Strong Year for MIMEDX Anticipate Full Year 2023 Potential to Build Cash Expect Adjusted EBITDA Revenue Growth Balance to $90+ Million Margin in 2H:23 Above Percentage in the Mid- by Year End 2023 20%, Driving Leverage to-High Teens as the Business S
Slide 16: Closing Remarks & Q&A
Helping Humans Heal Closing Remarks & Q&A